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ARSTRACT 
Objectives: To compare the incidence, clinical course, and sero- 
logic response to Bordetella antigens in patients with para- 
pertussis and pertussis. 
Design: Two studies were performed in Sweden during the 
199Os, when pettussis vaccines were used only in clinical trials. 
Study I was a retrospective study of patients with positive 
Bordetella cultures obtained in clinical routine, and study II 
involved an active search for patients with Bordetella infections 
during a placebo-controlled trial of a pertussis toxoid vaccine. 
Results: Study I includes 58, and study II 23 patients with para- 
pertussis. In study I, the incidence of parapet-tussis was 0.016 
cases per 100 person years in children 0 to 6 years old and 0 
in older children and adults. In study II, the incidence rates of 
parapet-tussis and pertussis were 0.2 and 16.2 per 100 per- 
son years, respectively, in children followed from 3 months to 
3 years of age. The median number of days with cough was 
21 in parapertussis and 59 in pertussis. The proportions of 
children with whooping and vomiting were lower in para- 
pertussis than in pertussis. Geometric mean serum filamen- 
tous hemagglutinin IgG increased from 6 to 63, and pertactin 
IgG from 4 to 12 units/ml in parapettussis patients, which was 
similar to increases in children with pertussis. 
Conclusions: Disease caused by Bordetella parapertussis is 
diagnosed less commonly and is milder and of shorter dura- 
tion than disease caused by Bordetella pertussis. Parapet-tus- 
sis induced serum IgG against filamentous hemagglutinin and 
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Bordetella parapertussis is closely related to Bordetella 
pertussis. The diseases caused by the two organisms are, 
according to several studies, similar, but parapertussis is 
milder and of shorter duration than pertussis.lm3 How- 
ever, this finding has been questioned by others.*a5 Symp- 
tomatic parapertussis infections are much less common 
than symptomatic pertussis infections.‘-3 A classic Dan- 
ish study of parapertussis suggests, that infections with 
the two organisms are equally common, but in paraper- 
tussis, the ratio of subclinical to clinical infection is much 
higher than in pertussis.’ 
Pertussis toxin (PI’) is one of the major virulence 
factors in B.pertussis. In contrast, B.parapertussis does 
not express PT, although it possesses the complete 
genome for the toxin.” Both organisms have at least two 
surface proteins, filamentous hemagglutinin @HA) and 
pertactin, which are identical or show a high degree of 
similarity.7,s Virtually all patients with pertussis have a 
serum antibody response to FHA, and a majority also 
respond to pertactin. 9~10 To date, little is known about 
the serologic response to FHA and pertactin in patients 
with parapertussis. 
The aims of the present two studies were to compare 
parapertussis and pertussis concerning incidence, clinical 
course, and the serum antibody response to FHA, per- 
tactin, and PT. 
MATERIAL AND METHODS 
This report is based on two studies performed in Giite- 
borg and surroundings in western Sweden from 1991 
through 1997. The incidence of pertussis had been high 
in Sweden since the beginning of the 1970s because the 
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Swedish whole-cell pertussis vaccine had become inef- 
fective around 1970, owing to several changes in vaccine 
production. l1 From 1979 through 1995 there was no 
licensed pertussis vaccine in the country. 
of the following criteria: (a) positive pertussis culture, 
(b) isolation of Bpertussis from a family member whose 
cough began within 28 days of the onset of the episode 
studied (before or after), (c) significant rise in PT IgG, 
and (d) significant rise in FHA IgG. These laboratory cri- 
Study I: Patients with Positive Parapertussis teria are included in the definition of pertussis proposed 
Cultures Found in Clinical Routine by the World Health Organization (WHO).‘* To these 
The Department of Clinical Bacteriology in Goteborg is 
the only laboratory that cultures Bordetella in the city of 
Goteborg and seven surrounding communities. The area 
had a mean total population of 642,000 from 1992 
through 1997. The mean population aged 0 to 6 years 
was 59,000. Cultures sent to this laboratory are obtained 
by physicians in primary health care and hospitals from 
patients seeking medicaI attention for suspected whoop- 
ing cough. Between November 1991 and November 1997 
all patients from whom B. parapertussis was isolated 
were identified from the laboratory records. If possible, 
their parents were interviewed concerning symptoms, 
with the use of a structured questionnaire. Furthermore, 
a serum sample from the child was requested. These sam- 
ples were obtained 7 to 30 weeks after onset of symp- 
toms. For comparison, all patients from whom B.petiussis 
was isolated during the same time period were identi- 
fied. They were not interviewed, and serum was not 
obtained from them. Individuals with positive paraper- 
tussis and pertussis cultures found in a vaccine efficacy 
trial (study II) are not included in study I. One individual 
from whom both B.pertussis and B.parapertussis were 
isolated is not included in this report. 
Study II: Active Search for Parapertussis 
Cases during a Vaccine Effkacy Trial 
In a placebo-controlled, double-blind efficacy trial of an 
acellular pertussis vaccine, consisting of pertussis toxoid 
alone, 3450 infants were randomized to vaccination with 
diphtheria-tetanus toxoids alone (DT, Statens Seruminsti- 
tut, Copenhagen, Denmark) or to the same DT with per- 
tussis toxoid (DTaP, North American Vaccine Inc., 
Beltsville, Maryland, USA) at 3,5, and 12 months of age.12J3 
The trial was performed in the Goteborg area of western 
Sweden during 1991 to 1995. 
During the follow-up period, Bordetella infections 
were actively sought and diagnosed in both study chil- 
dren and family members. All families were interviewed 
by a study nurse once a month. Parents were instructed 
to contact the nurse if a study child or a family member 
coughed for 7 days or more. A nasopharyngeal culture 
and an “acute” serum were obtained. A convalescent 
serum was taken about 4 to 6 weeks later. A total of 3450 
study children, 2940 siblings, and 6466 parents were fol- 
lowed prospectively. The observation periods were 9008, 
7104, and 17,610 person years in study children, siblings, 
and parents, respectively, In this study pertussis was 
defined as cough for 7 days or longer and one or more 
were added (e) significantly elevated IgG antibodies 
against PT and FHA in a convalescent serum if no acute 
serum was availabIe.12 Parapertussis was defined as cough 
for 7 days or longer and a positive parapertussis culture 
or fulfilment of at least two of the following criteria: 
(a) significant rise in FHA IgG without significant rise in 
PT IgG, PT IgM, and PT IgA, (b) parapertussis DNA 
detected by the polymerase chain reaction (PCR), and 
(c) isolation of B. parapertussis from a family member 
whose cough began within 28 days of the onset of the 
episode studied (before or after). The clinical follow-up 
of patients with pertussis and parapertussis continued 
until the cough ended, or for at least 60 days. Three indi- 
viduals with concurrent laboratory-confirmed pertussis 
and parapertussis infections are not included in this 
report. 
Laboratory Assays 
Nasopharyngeal swabs taken in clinical routine (study I) 
were cultured on Regan-Lowe medium.lj In the vaccine 
efficacy trial (study II), nasopharyngeal swabs were cul- 
tured on Regan-Lowe medium and in an enrichment 
medium (Regan-Lowe with 50% charcoal agar). Borde- 
tella pertussis and B. parapertussis colonies were veri- 
fied by Gram-stain, agglutination, and biochemical’tests: 
In study II, the secretions from the nasopharyngeal swabs 
also were examined by PCR for B.pertussis and B.parq- 
pertussis DNA.16J7 
Serum IgG antibodies against PT, FHA, and pertactin 
were measured by enzyme-linked immunosorbent assay 
(ELISA).9,‘2 Sera were tested in eight threefold dilutions, 
starting with a 1: 10 dilution. All sera from the same child 
were assayed on the same microtiter plate. Petussis toxin 
was obtained from NAVA Inc., Beltsville, Maryland, USA. 
Filamentous hemagglutinin (lot 10,000) was obtained 
from Institut Pasteur-Merieux, Marcy I’Etoile, France. Per- 
tactin was obtained from Chiron Vaccines, Siena, Italy. 
The reference sera used were the United States Food and 
Drug Administration (US FDA) reference pertussis antisera 
lot 3 (for PT and FHA) and lot 4 (for pertactin). Lot 3 
contained 200 units/ml of PT IgG and FHA IgG. Lot 4 
contained 90 units/ml of pertactin IgG. Antibody con- 
centrations were calculated with the reference line 
assay. ‘* The mimimal level of detection was 1 unit/ml 
for all assays. Sera with IgG of less than 1 unit/ml were 
arbitrarily assigned a value of 0.5 units/ml. For all IgG 
antibodies, an increase of twofold or more from the acute 
to the convalescent serum was considered significant if 
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the concentration in the convalescent serum was 7 or 
more units/ml. In study II, 42 children with pertussis 
were randomly selected for determination of PT, FHA, 
and pertactin IgG, for comparison with the 18 paraper- 
tussis patients from whom paired sera were available. 
Statistics 
Proportions were compared with Fisher’s exact test. Dura- 
tion of clinical symptoms was compared with Mann- 
Whitney test. Geometric mean values were compared 
with paired t-test. All P-values are two-tailed. 
Ethics 
Study I was approved by the Ethics Committee, Gijteborg 
University All parents gave oral consent after receiving 
oral and written information. Study II was approved by 
the NICHD, the US FDA, the Medical Products Agency, 
Uppsala, Sweden, and the Ethics Committee, Gijteborg 
University. All parents gave written consent after receiv- 
ing oral and written information. 
RESULTS 
Incidence, Age, and Sex Distribution 
Stzcdy I 
Bordetella parapertussis was isolated from 58 and B.per- 
tussis from 3481 individuals from November 1991 
through November 1997 at the Department of Clinical 
Bacteriology in Gijteborg after exclusion of all patients 
with positive cultures who are included in study II. Bor- 
detella parapertussis constituted 1.6% of all Bordetella 
isolates. Of the 58 parapertussis patients, 25 were boys 
and 33 girls. Their ages ranged from 2 to 81 months 
(median 25 mo). In the age group 0 to 6 years the doc- 
umented incidence of parapertussis was 0.016 per 100 
person years. The documented incidence rates of para- 
pertussis and pertussis in all age groups were 0.0015 and 
0.09 per 100 person years, respectively. 
Study II 
During the vaccine efficacy trial, parapertussis was diag- 
nosed in 23 (18 culture-confirmed) and pertussis in 1213 
(618 culture-confirmed) individuals. Table 1 presents num- 
bers of cases, incidence rates, and proportions of para- 
pertussis among all Bordetella cases in the different 
groups. The incidence of parapertussis was 0.20 per 100 
person years in all study children (vaccinated plus non- 
vaccinated). The difference in incidence of parapertussis 
between children who were (0.24 per 100 person years) 
and were not (0.16 per 100 person years) vaccinated 
with pertussis toxoid was not significant. The proportion 
of parapertussis cases among all Bordetella infections 
was significantly higher in the pertussis toxin-vaccinated 
group (3.5% vs. l%, P < 0.01). Of the 23 parapertussis 
cases, 14 were boys and 9 girls. Their ages ranged from 
4 to 114 months (median 23 mo). Of 1126 children with 
pertussis in study II, 51% were girls. The median age of 
the children with pertussis was 30 months. 
Clinical Picture 
Table 2 summarizes data on cough, whooping attacks, 
and vomiting in patients with parapertussis and pertus- 
sis in studies I and II. There was no clinical difference 
between parapertussis in study I, in which cases were 
found passively from the laboratory, and study II, in which 
cases were actively sought among patients with cough. 
The duration of cough and paroxysmal cough and the 
duration and frequency of whooping attacks and vomit- 
ing were significantly lower in parapertussis than in per- 
tussis patients in study II. 
In study I none of the 58 parapertussis patients were 
hospitalized, whereas 125 of the 3481 patients (3.6%) 
with pertussis were hospitalized. In study II no patient 
with BordeteZZa infection was hospitalized. 
Antibody Response 
FUamentous Hemagglutinin IgG 
Geometric mean (GM) values increased significantly both 
in parapertussis and in pertussis patients in study II. The 
range and GM in convalescent sera were similar after 
both diseases. The proportions of patients with significant 
increases did not differ significantly (parapertussis: 14/18, 
77%; pertussis: 40/42, 95%). Filamentous hemagglutinin 
Table 1. Numbers of Cases and Incidence Rates of Parapertussis and Pertussis and Proportions of Parapertussis 
Cases among All Bordetella Infections in a Randomized, Prospective Vaccine Efficacy Trial (Study II) 
Subjects 
DTaP-vaccinated study children 
DT-vaccinated study children 
Siblings 
Parents 
Parapetfussis Pertussis 
n (Incidence*) n (Incidence*) 
11 (0.24) 302 (6.60) 
7 (0.16) 713 (16.20) 
5 (0.07) 111 (1.60) 
0 0 87 (0.49) 
Proportion Parapetiussis 
among A// Bordetella infections (%) 
3.5 
1.0 
4.3 
0 
*Incidence rates = number of cases per 100 person years. 
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Table 2. Duration and Numbers of Patients with Certain Symptoms in Parapertussis and Pertussis 
Symptom 
Cough 
Duration (d) 
Paroxysmal cough 
Duration (d) 
Number (%) 
Whooping attacks 
Duration (d) 
Number (%) 
Study /* 
Parapertussis (n = 46) 
21 (4-80) 
14 (O-72) 
43 (93%) 
0 (O-25) 
14 (30%) 
Parapetiussis (n = 23) 
21 (7->60) 
15 (0->60) 
22 (96%) 
0 (O-8) 
2 (9%) 
Study /I+ 
Pertussis (n = 950) 
59 (7->60) 
51 (0->60) 
946 (>99%) 
20 (0->60) 
675 (71%) 
P-Value 
< 0.001 
< 0.001 
NS 
< 0.001 
< 0.001 
Vomiting 
Duration (d) 
Number (%) 
0 (O-30) 
21 (46%) 
0 (O-7) 
9 (39%) 
18 (0->60) 
730 (77%) 
< 0.001 
< 0.001 
Duration = median number of days (range). 
*In study I, clinical data ware obtained from 46 of 58 children with paraperiussis. In study II, clinical data were obtained from all 23 patients with parapettussis. Of the 
1213 patients with pertussis in study II, only the 950 children who had not received any periussis vaccine are included. NS = not significant. 
(FHA) IgG levels in the convalescent sera of children in of 18 (78%) for FHA versus 9 of I6 (56%) for pertactin 
study I were similar to those in study II (Table 3). (nonsignificant). 
Pet-tact&a IgG Pertussis Toxin IgG 
Geometric mean values increased significantly both in 
parapertussis and in pertussis patients in study II. The 
range and GM in convalescent sera were similar after 
both diseases. The proportions of patients with significant 
increases did not differ significantly (parapertussis: 9/16, 
56%; pertussis 29/42, 69%). Pertactin IgG levels in the 
convalescent sera of children in study I were similar to 
those in study II. 
Pertactin IgG in paired sera was a less sensitive diag- 
nostic tool than FHA IgG. Among pertussis patients 40 of 
42 (95%) had significant FHA IgG increases, whereas 29 
of 42 (69%) had pertactin IgG increases (F < 0.003). Cor- 
responding figures for the parapertussis patients were 14 
Of the 42 pertussis patients in study II, 40 had significant 
PT IgG increases, whereas none of the 18 parapertussis 
patients had a significant PT IgG increase (P < 0.001). 
Among all 55 parapertussis patients in studies I and II 
from whom convalescent sera were available, 26 had 
detectable PT IgG. Of those, 19 were vaccinated with p&-- 
tussis toxoid, and 7 were never vaccinated with any per- 
tussis vaccine. In three of these seven patients PT IgG 
was low and possibly nonspecific (l-4 units/ml). One 
patient with a positive parapertussis culture had high PT 
IgG in a single convalescent serum (118 units/ml), sug- 
gesting mixed pertussis and parapertussis infection. The 
remaining three patients had PT IgG between 13 and 
Table 3. Geometric Mean and Range of Serum Concentrations of IgG Antibodies against Filamentous 
Hemagglutinin, Pertactin, and Pettussis Toxin, in Patients with Parapertussis and Pertussis 
FHA IgG (U/ml) 
Acute 
Convalescent 
P-value+ 
Pertactin IgG (U/ml) 
Acute 
Convalescent 
P-value+ 
PT IgG (U/ml) 
Acute 
Convalescent 
P-value+ 
Study I 
Parapet&As (n = 37) 
GM (Range) 
Parapetfussis (n = 18*) 
GM (Range) 
Study /I 
Pertussis (n = 42) 
GM (Range) 
Not obtained 
46.0 (1 i-345) 
6.0 (d-209) 
63.0 (12-198) 
<O.OOl 
Not obtained 
16.0 (2.7-69) 
4.3 (<i-21) 
12.0 (1.8-48) 
<O.OOl 
Not obtained 
2.4 (<I->400) 
6.4 (<l-116) 
5.1 (<l-69) 
NS 
1.5 (<l-16) 
84.0 (<I->400) 
<O.OOl 
2.8 (<l-33) 
16.0 (2.2-356) 
<O,OOi 
1.5 (<I ->400) 
125.0 (4->400) 
<O.OOl 
*For pertactin IgG 16 paired sera were available; +acute versus convalescent. 
GM = geometric mean: FHA = filamentous hemagglutinin; PT = pertussis toxin. 
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42 units/ml in the convalescent sera, which is lower than 
usually seen in convalescent sera of patients with recent 
pertussis, suggesting that a clinical or subclinical B.per- 
tussis infection may have preceded their parapertussis. 
DISCUSSION 
A comparison between studies I and II shows, as 
expected, that registration of cases of parapertussis from 
laboratory reports underestimates the true incidence of 
the disease. An active search for cases among patients 
who cough is necessary to approach the true incidence 
of symptomatic infections. Study II yielded an incidence 
of parapertussis in children aged 0 to 3 years that was 
12.5 times higher than the incidence in 0- to 6-year-old 
children in study I. The incidence of pertussis is also con- 
siderably underestimated when based on laboratory 
rep0rts.l’ There are several obvious reasons for this. Many 
patients with Bordetella infections never seek medical 
attention. If they do, cultures might not be obtained if 
the pertussis diagnosis is obvious from the clincial pic- 
ture or if the disease is never suspected by the physi- 
cian. Furthermore, cultures have a sensitivity of about 50 
to 70% when taken under optimal conditions and even 
lower in clinical practice.12,19,20 
Two prospective vaccine efficacy trials with active 
search for B.parapertussis infections among infants and 
young children who coughed were reported previously, 
one in Italy and one in Germany. These studies yielded 
incidence rates of 0.21 and 0.6 to 0.9 cases per 100 per- 
son years, respectively,3,10 which can be compared with 
0.2 cases per 100 person years in the study children in 
the vaccine efficacy trial reported here. Even though the 
incidence rates were similar between the studies, the pro- 
portions of parapertussis cases among all Bordetella infec- 
tions in vaccinated and nonvaccinated study children 
were much higher in the Italian and German studies (12% 
and 40%, respectively) than in the present study II (1.7%). 
The incidence of pertussis in Italy and Germany was 
much lower than in Sweden when the trials were per- 
formed. Incidence rates of pertussis fulfilling slightly dif- 
ferent variations of the pertussis definition proposed by 
the World Health Organization in the nonvaccinated con- 
trol children (DT recipients) were 3.5,3.0, and 10.3 cases 
per 100 person years in Italy, Germany, and Sweden, 
respectively.10JZ~1*~21 Th ese pronounced differences in per- 
tussis incidence and the higher ratio of parapertussis to 
pertussis infections may be attributable to differences in 
pertussis vaccination rates. In Sweden, virtually no per- 
tussis vaccine was given outside of clinical trials, whereas 
the vaccination rates with whole-cell pertussis vaccines 
of infants in Italy and Germany were 15% and 40%, 
respectively.‘O,Z1 
A recent study from Finland concluded that para- 
pertussis is a common disease in a country with a high 
vaccination rate against pertussis with a whole-cell vac- 
cine. In that study, 32% of the Bordetella infections were 
caused by B. parapertussis, and 7% were mixed infec- 
tions.22 This could lead to speculations that parapertus- 
sis increases if pertussis decreases. However, the 
incidence of parapertussis was only 0.0034 cases per 100 
person years in the Finnish study, which is similar to the 
present study I (0.0015 per 100 person years) that was 
performed in a population with little use of pertussis vac- 
cines. In the authors’ opinion, both studies show that 
parapertussis is an uncommon disease, and the twofold 
difference in incidence between Finland and Sweden can 
be explained partly by the addition of PCR to cultures in 
the Finnish study, whereas the present Swedish study 
used only cultures. Furthermore, the present study II 
shows that the absolute incidence of parapertussis does 
not increase in pertussis toxoid-vaccinated children even 
though its relative incidence compared to pertussis 
increases. It is even possible, in a longer perspective, that 
the absolute incidence of parapertussis will decrease in 
Sweden when the incidence of pertussis decreases owing 
to vaccination. A study in animals showed that paraper- 
tussis infection is facilitated by concurrent infection with 
pertussis. 23 If that is the case also in humans, a decrease 
in the incidence of pertussis may decrease spread of and 
infection with B. parapertussis. It is also theoretically 
possible that pertussis vaccines including antigens com- 
mon to both organisms also may protect against para- 
pertussis. One study testing two three-component 
acellular pertussis vaccines (PT, FHA, and pertactin) 
showed no significant efficacy against parapertussis; 
another study testing a four-component vaccine m, FHA, 
pertactin and fimbriae-2) showed a tendency to protec- 
tion that did not reach significance.3J0 
The present and a previous study show that the age 
and sex distribution of symptomatic parapertussis infec- 
tions do not differ from those of symptomatic pertussis 
infections,’ with the exception that parapertussis cases 
in adults were not found in the present studies I and II. 
Two recent studies have emphasized the similarities 
of the clinical picture of pertussis and parapertussis.4a22 
In both studies the prevalence of symptoms were com- 
pared at the time the patients sought medical attention, 
but the patients were not followed until the symptoms 
ended. The present and several previous studies that have 
followed the patients until symptoms ended show that 
parapertussis is a considerably milder disease than per- 
tussis.1-3 All variables compared (cough, paroxysmal 
cough, vomiting, and whooping attacks) were of shorter 
duration or seen in lower frequency in parapertussis than 
in nonvaccinated pertussis patients. It should be noted 
that pertussis in vaccinated children was significantly 
milder (P < 0.001 for all variables compared) than in non- 
vaccinated children in the efficacy trial, on which the 
current study II is based.12 Thus, pertussis in vaccinated 
children may resemble parapertussis. 
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The possibility that some patients with verified para- 
pertussis were infected with both organisms should be 
considered, because this may be an underreported occur- 
rence.22,24 However, in the present two studies with a 
total of 81 parapertussis cases the authors found four 
additional patients with confirmed mixed infections (not 
described in the article). The only way of excluding a co- 
infection with pertussis in parapertussis patients is to 
compare pertussis toxin antibodies in acute and con- 
valescent sera. 
This study showed, in agreement with other studies, 
that the antibody response to FHA is an almost universal 
occurrence in both pertussis and parapertussis 
patients. 9,10 Notably, parapertussis patients responded to 
FHA purified from a strain of B. pertussis, and the mag- 
nitude of the antibody response was similar in the two 
groups. Likewise, the antibody response to pertactin, 
derived from a strain of Bpertussis, was similar in para- 
pertussis and pertussis patients. Some patients with para- 
pertussis and pertussis had little or no response to 
pertactin. This is in agreement with two considerably 
larger studies that showed that an antibody response to 
pertactin is a less consistent finding than an antibody 
response to PT and FHA in patients with pertussis.9J0 
It has been shown previously that pertussis with a 
typical clinical picture can occur after pampertussis.25 This 
study suggests that the reverse also may be true: paraper- 
tussis may occur despite previous B.pertussis infection. In 
both study I and study II, a few individuals with paraper- 
tussis had pertussis toxin antibodies without having been 
vaccinated. Since pertussis toxin is unique to B.pertussis 
with no known cross-reacting antigens, the finding of per- 
tussis toxin antibodies in nonvaccinated individuals is 
strong evidence of previous infection with B.pertussis. 
The lack of cross-protection between the two species and 
the inability of multicomponent acellular pertussis vac- 
cines containing both FIIA and pertactin to protect against 
B. parapertussis cast doubt on their importance as pro- 
tective antigens in Bordetella infections3.10 
CONCLUSIONS 
The two studies show that B. parapertussis infections 
are underdiagnosed in clinical routine but still are uncom- 
mon, even when active search is performed. The clinical 
presentation of parapertussis is similar to that of pertus- 
sis, but the former disease is milder and of shorter dura- 
tion. Parapertussis induces serum antibodies against FHA 
and pertactin from B.pertussis of similar magnitude to 
that of pertussis, indicating homology or close similarity 
of these two surface proteins from the two species. 
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